论文部分内容阅读
目的探讨辛伐他汀对冠心病患者血浆NO和NOS的影响。方法将98例冠心病住院患者随机分为常规治疗组、辛伐他汀组及联合治疗组,采用硝酸还原酶法,在治疗前后抽血检测血中NO和NOS水平。结果各组冠心病患者在8周前,其血浆NO和NOS水平没有差异(F=4.86,3.53P>0.05),在治疗8周后存在着明显的差异(F=17.63,11.07P<0.05),各组在治疗后血浆NO和NOS水平均明显增高,以联合治疗组增高最明显,其次是辛伐他汀组和常规治疗组。结论辛伐他汀可通过增加血浆NO和NOS的浓度来改善冠心病患者的血管内皮功能,该作用可能是通心络防治冠心病的机制之一。
Objective To investigate the effect of simvastatin on plasma NO and NOS in patients with coronary heart disease. Methods 98 cases of coronary heart disease inpatients were randomly divided into routine treatment group, simvastatin group and combination therapy group. Nitric acid reductase method was used to detect the levels of NO and NOS in blood before and after treatment. Results There was no difference in plasma NO and NOS levels between the two groups (F = 4.86, 3.53P> 0.05), and there was a significant difference after 8 weeks of treatment (F = 17.63, 11.07 P <0.05) , Plasma NO and NOS levels in all groups were significantly increased after treatment, the most obvious increase in combination therapy group, followed by simvastatin group and conventional treatment group. Conclusion Simvastatin can improve endothelial function in patients with coronary heart disease by increasing plasma concentrations of NO and NOS, which may be one of the mechanisms of Tongxinluo in preventing and treating coronary heart disease.